Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study-Reference-Cited by-同舟云学术

Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study

Published:2023-05-10 Issue:2 Volume:23 Page:129-140
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Wang Tianyou,Zhu Xiaofan,Chen Yumei,Shen Shuhong,Tang Yongmin,Zhang Jingying,He Yingyi,Zhang Hui,Gao Ju,Fang Jianpei,Liu Rong,Wu Xiaoyan,Sun Jinchuan,Zhang Minlu

Funder

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40268-023-00420-y.pdf

Reference42 articles.

1. Adeyinka A, Bashir K. Tumor Lysis Syndrome. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021. http://www.ncbi.nlm.nih.gov/books/NBK518985/. Accessed 2 Dec 2021.

2. Myint PT, Butt HW, Alrifai T, Marin C. Spontaneous tumor lysis syndrome secondary to small-cell neuroendocrine carcinoma of unknown origin: a rare case report and literature review. Case Rep Oncol Med. 2019;2019:e6375693.

3. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.

4. Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. J Clin Oncol. 2003;21:4402–6.

5. Coiffier B. Acute tumor lysis syndrome—a rare complication in the treatment of solid tumors. Onkologie. 2010;33:498–9.